Risky alcohol use among patients dispensed opioid medications: A clinical community pharmacy study
- PMID: 35316690
- PMCID: PMC9018607
- DOI: 10.1016/j.drugalcdep.2022.109406
Risky alcohol use among patients dispensed opioid medications: A clinical community pharmacy study
Abstract
Background: Included among the significant risk factors for opioid overdose is concomitant use of other central nervous system depressants, particularly alcohol. Given the continued expansion of community pharmacy in the continuum of care, it is imperative to characterize alcohol use among pharmacy patients dispensed opioids in order to establish a foundation for identification and intervention in these settings.
Methods: This secondary analysis utilized data from a one-time, cross-sectional health assessment conducted among patients dispensed opioid medications in 19 community pharmacies in Indiana and Ohio. Adult, English speaking, patients not receiving cancer care who were dispensed opioid medications were asked to self-report alcohol and substance use, behavioral and physical health, and demographic information. Descriptive and logistic regression analyses were employed to characterize alcohol use/risky alcohol use and patient characteristics associated therewith.
Results: The analytical sample included 1494 individuals. Participants were on average 49 years of age (Standard Deviation=14.9)-with 6% being persons of color (n = 89). Weekly drinking was reported by 18.1% (n = 204) and daily drinking was reported by 6.8% (n = 77) of the study sample, with a total of 143 (9.6%) participants reporting moderate/high risk drinking. Males (Adjusted Odds Ratio [AOR]=1.94, 95% CI=1.3,2.9), those with higher pain interference (AOR=1.44, 95% CI=1.0,2.0), overdose history (AOR=1.93, 95% CI=1.1,3.5), sedative use (AOR=2.11, 95% CI=1.3,3.5), and tobacco use (AOR=2.41, 95% CI=1.6,3.7) had increased likelihood of moderate/high risk alcohol use (all p < 0.05).
Conclusions: Medication labeling and clinical guidelines clearly indicate that patients should abstain from concomitant use of opioids and alcohol. This study has identified rates and associated risk factors of risky alcohol use among a clinical sample of community pharmacy patients dispensed opioid medications. Continuing this line of research and potential clinical service development has the ability to improve patient safety through addressing a significant gap within the current opioid epidemic.
Keywords: Alcohol use; And opioid medication; Community pharmacy.
Copyright © 2022 Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of Interest
No conflicts declared
Figures



Similar articles
-
Associations between elevated depressive symptoms and substance use, prescription opioid misuse, overdose history, pain, and general health among community pharmacy patients prescribed opioids.Subst Abus. 2022;43(1):1110-1115. doi: 10.1080/08897077.2022.2060450. Subst Abus. 2022. PMID: 35499399 Free PMC article.
-
Opioid medication misuse among unhealthy drinkers.Drug Alcohol Depend. 2017 Oct 1;179:13-17. doi: 10.1016/j.drugalcdep.2017.06.013. Epub 2017 Jul 14. Drug Alcohol Depend. 2017. PMID: 28735077 Free PMC article.
-
Pain Severity and Interference and Substance Use Among Community Pharmacy Patients Prescribed Opioids: A Secondary Analysis of the PHARMSCREEN Study.J Pain. 2022 Aug;23(8):1448-1459. doi: 10.1016/j.jpain.2022.03.238. Epub 2022 Apr 11. J Pain. 2022. PMID: 35417791 Free PMC article.
-
Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis.Drug Alcohol Depend. 2020 Nov 1;216:108238. doi: 10.1016/j.drugalcdep.2020.108238. Epub 2020 Aug 19. Drug Alcohol Depend. 2020. PMID: 32891910
-
Application of a diazepam milligram equivalency algorithm to assess benzodiazepine dose intensity in Rhode Island in 2018.J Manag Care Spec Pharm. 2022 Jan;28(1):58-68. doi: 10.18553/jmcp.2022.28.1.58. J Manag Care Spec Pharm. 2022. PMID: 34949119 Free PMC article.
Cited by
-
Barriers and facilitators to the implementation of screening and intervention for co-use of opioid medications and alcohol among community pharmacy patients.J Subst Use Addict Treat. 2025 Feb;169:209606. doi: 10.1016/j.josat.2024.209606. Epub 2024 Dec 12. J Subst Use Addict Treat. 2025. PMID: 39672335
References
-
- Amato L, Minozzi S, Davoli M, Vecchi S, 2011. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev (9), Cd005031. - PubMed
-
- Armoon B, SoleimanvandiAzar N, Rostami M, Higgs P, Bayani A, Bayat AH, Mohammadi R, Ahounbar E, Fattah Moghaddam L, 2021. Drug type and risk behaviors associated with non-fatal overdose among people who use drugs: a systematic review and meta-analysis. J Addict Dis, 1–12. - PubMed
-
- Brands B, Blake J, Marsh DC, Sproule B, Jeyapalan R, Li S, 2008. The impact of benzodiazepine use on methadone maintenance treatment outcomes. J Addict Dis 27(3), 37–48. - PubMed
-
- Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA, 1998. The AUDIT Alcohol Consumption Questions (AUDIT-C): An effective brief screening test for problem drinking. Arch Intern Med 158(16), 1789–1795. - PubMed
-
- CDC, 2013. Select features of state pharmacist collaborative practice laws. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous